Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Ligand Pharmaceuticals Company Profile (NASDAQ:LGND)

Consensus Ratings for Ligand Pharmaceuticals (NASDAQ:LGND) (?)
Ratings Breakdown: 2 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.71)
Consensus Price Target: $86.48 (8.37% upside)

Current Analysts' Coverage Summary for Ligand Pharmaceuticals (NASDAQ:LGND)
Show:
DateFirmActionRatingPrice TargetDetailsShare
4/1/2015Deutsche BankBoost Price TargetBuy$74.00 -> $94.00ViewTweet This Rating  Share This Rating on StockTwits
3/5/2015Cantor FitzgeraldSet Price TargetHold$46.00 -> $65.00ViewTweet This Rating  Share This Rating on StockTwits
3/3/2015CRT CapitalInitiated CoverageBuy$102.00ViewTweet This Rating  Share This Rating on StockTwits
2/9/2015TheStreetUpgradeHold -> BuyViewTweet This Rating  Share This Rating on StockTwits
1/28/2015Roth CapitalSet Price TargetBuy$116.00ViewTweet This Rating  Share This Rating on StockTwits
1/20/2015ZacksUpgradeUnderperform -> Neutral$55.40ViewTweet This Rating  Share This Rating on StockTwits
10/8/2014ING GroupReiterated RatingBuyViewTweet This Rating  Share This Rating on StockTwits
2/21/2014Griffin SecuritiesSet Price Target$95.00ViewTweet This Rating  Share This Rating on StockTwits
2/2/2014Craig HallumSet Price Target$90.00ViewTweet This Rating  Share This Rating on StockTwits
3/25/2014Brinson PatrickSet Price Target$98.00ViewTweet This Rating  Share This Rating on StockTwits
4/28/2014Ned Davis ResearchUpgradeSell -> NeutralViewTweet This Rating  Share This Rating on StockTwits
2/24/2014Summer StreetBoost Price TargetBuy$78.00 -> $91.00ViewTweet This Rating  Share This Rating on StockTwits
2/10/2014MLV & Co.Boost Price TargetBuy$82.00ViewTweet This Rating  Share This Rating on StockTwits
10/31/2013Brean CapitalDowngradeBuy -> Hold$45.00ViewTweet This Rating  Share This Rating on StockTwits
(Data available from 5/4/2013 forward)